(266 days)
No
The description mentions a "proprietary algorithm" for processing data and calculating parameters, but there is no mention of AI, ML, or any related concepts like training sets, test sets, or image processing, which are typically associated with AI/ML applications in medical devices. The algorithm appears to be a deterministic calculation based on measured electrical signals.
No.
The device is indicated for measurement and monitoring, not for providing therapy or treatment.
No
The device is explicitly stated as "not for use as a sole diagnostic screening tool." While it collects and displays measurements that "correlate to epithelial integrity," its primary indicated use is related to enteral feeding, gastric decompression, and monitoring purposes, not for making a definitive diagnosis on its own.
No
The device description explicitly states it is an "electronic device" that "delivers electrical current" and includes "electronic circuits of the monitor," indicating it has significant hardware components beyond just software.
Based on the provided information, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices intended for use in vitro for the examination of specimens, including blood, tissue, and urine, derived from the human body, to provide information for diagnostic, monitoring, or compatibility purposes.
- Device Function: The Mucosal Impedance Measurement System directly measures electrical properties of the gastric tissue in vivo (within the living body) through a catheter inserted into the gastric tract. It does not examine specimens in vitro.
- Intended Use: The intended use is to collect and display real-time and continuous gastric reactance measurements in patients requiring gastric decompression or enteral feeding. While these measurements might provide information relevant to a patient's condition, the device itself is not performing a diagnostic test on a biological sample outside the body.
- Device Description: The description clearly states the device delivers electrical current to a region of gastric tissue and measures the resultant voltage in vivo.
Therefore, the Mucosal Impedance Measurement System falls under the category of an in vivo diagnostic or monitoring device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The Mucosal Impedance Measurement System is indicated for use by medical personnel trained in the usage of enteral feeding tubes for the treatment of adult patients requiring gastric decompression or enteral feeding for the delivery nutrition, fluids, and medications to the patient from an enteral feeding syringe or feedings set designed with ENFit connectors. The measurements of the Mucosal Impedance Measurement System are collected in patients indicated for enteral feeding. This product is single use for no longer than 24 hours.
The Mucosal Impedance Measurement System is equipped with sensors designed to collect and display real time and continuous gastric reactance "XL" measurements. The device is not for use as a sole diagnostic screening tool and is restricted to prescription use in a hospital environment.
Product codes (comma separated list FDA assigned to the subject device)
QIS, PIF
Device Description
The Mucosal Impedance Measurement System senses passive electrical features of the gastric tissue that corelate to of epithelial integrity through a technique known as 'bioimpedance spectroscopy'. Bioimpedance spectroscopy measures the ability of tissue to conduct electricity (resistance) and the ability of tissue to store charged particles (reactance).
The Florence monitor model ISMO 1.0 is an electronic device that delivers electrical current to a small region of the gastric tissue through the Athena Catheter; the device measures the resultant voltage, and then calculates and displays impedance information in numeric and graphic representations. More specifically, to measure the bioimpedance of the gastric mucosa impedance, the device delivers electric current through the Athena Catheter. The resulting voltage developed between the two inner electrodes is sensed, filtered, amplified, and then digitized by the electronic circuits of the monitor. Once the measured voltage from the gastric tissue has been digitized, a proprietary algorithm processes the information and calculates the impedance spectrum and the Central Reactance parameter (XL). The device displays the information as either a function of frequency or as a function of time.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
gastric tissue, upper gastric tract, gastric mucosa
Indicated Patient Age Range
adult patients
Intended User / Care Setting
medical personnel trained in the usage of enteral feeding tubes; hospital environment.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical/bench studies conducted on the Mucosal Impedance Measurement System to demonstrate the safety and effectiveness of the device include Sterilization Validation, Packaging Validation, Shelf Life testing, Biocompatibility testing per ISO 10993-1, Software Verification and Validation, Electrical Safety and EMC testing, Performance testing for tensile properties, security of connectors, flow rate, and liquid leakage. The EnFit feeding connector of the Athena Catheter was tested per ISO 80369-3.
Test: Flow rate
Methods: "Gravity Flow Rate Testing in Enteral Tubes" as described in the "Catalog of Regulatory Science Tools to Help Assess New Medical Devices"
Test: Tensile strength
Methods: EN1615:2000 Enteral Feeding Catheters And Enteral Giving Sets For Single Use And Their Connectors. Design And Testing (Section 4.1.1); EN1618:1997 Catheters other than intravascular catheters - Test methods for common properties (Annex B)
Test: Liquid leakage
Methods: EN1615:2000 Enteral Feeding Catheters And Enteral Giving Sets For Single Use And Their Connectors. Design And Testing (Sections 4.1.3); EN1618:1997 Catheters other than intravascular catheters - Test methods for common properties (Annex C)
Test: Security of connectors
Methods: EN1615:2000 Enteral Feeding Catheters And Enteral Giving Sets For Single Use And Their Connectors. Design And Testing (Sections 4.3.1); EN1618:1997 Catheters other than intravascular catheters - Test methods for common properties (Annex F)
Test: Flexibility
Methods: ASTM F3505-21 Standard Test Method for Stent and Endovascular Prosthesis Kink Resistance
Test: EnFit connector (dimensional verification, rigidity, fluid leakage test, stress cracking, resistance to separation from axial load, resistance to unscrewing, resistance to overriding, and disconnection by unscrewing)
Methods: ISO 80369-3:2016 Small-bore connectors for liquids and gases in healthcare applications Part 3: Connectors for enteral applications
Test: Sterilization validation
Methods: ISO 11135:2014 Sterilization of health-care products Ethylene oxide - Requirements for the development, validation and routine control of a sterilization process for medical devices
Test: Packaging validation
Methods: ISO 11607-1:2019 Packaging for terminally sterilized medical devices - Part 1: Requirements for materials, sterile barrier systems and packaging systems
Test: Dimensional verification
Methods: Overall length, working length, catheter outer diameter, catheter inner diameter, sensor dimensions, and spacing of the sensors
Test: Accuracy - thermal stability
Methods: Thermal stability of the sensors has been verified by confirming that the measurements of the central reactance parameter (XL) remain consistent across a temperature range that covers the range 77-111°F (25-44°C). Stability of the sensors was confirmed in terms of the dispersion (standard deviation / interquartile range) of a statistically significative number of measurements across the temperature range. The PASS criterion was defined as confirming that at least 95% of all measurements are contained within a +/-1Ω tolerance.
Test: Accuracy - temporal stability
Methods: Temporal stability of the sensors was verified by confirming that the measurements of the central reactance parameter (XL) remain consistent across 24 hours. Stability of the sensors was confirmed in terms of the dispersion (standard deviation / interquartile range) of a statistically significative number of measurements over the 24 period. The PASS criterion was defined as confirming that at least 95% of all measurements are contained within a +/-1Ω tolerance (which corresponds to the accuracy stated in the Instructions for Use).
Key results: In all instances, the Mucosal Impedance Measurement System functioned as intended.
Biocompatibility: The Athena Catheter was evaluated according to the FDA guidance (2023) "Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process". The following biocompatibility endpoints were assessed for the Athena Catheter: Toxicity, Irritation, Sensitization. Results support the biocompatibility of the Athena Catheter.
Software: A failure or flaw of the software functions of the Mucosal Impedance Measurement System does not present a hazardous situation with a probable risk of death or serious injury to a patient, user of the device, or others in the environment of use. Therefore, the required level of documentation identified under FDA Guidance document "Content of Premarket Submissions for Device Software Functions" is basic documentation.
Electrical Safety and Electromagnetic Compatibility: The test reports address the basic safety evaluation (which includes electrical safety testing) per the FDA consensus standard IEC-60601-1.2005, AMD1.2012. Additionally, EMC testing was conducted per IEC-60601-1-2.2014, and passed the applicable clauses. The results support the electrical safety and EMC of the device.
Human factors: The Florence monitor and the Athena catheter's usability has been validated in an actual clinical environment to support the safety and effectiveness of the device for their intended users and environment. This process was completed in accordance with the principles outlined in the "Applying Human Factors and Usability Engineering to Medical Devices" guidance. All evaluations have been performed according to EN 60601-1-6:2010, AMD1:2013 Medical Electrical Equipment - Part 1-6: General Requirements For Basic Safety And Essential Performance - Collateral Standard: Usability.
Animal Study: A GLP prospective, controlled animal trial was performed with two groups, control group (CG) N=5 and shock (MAP ≤ 48 mmHg) group (SG) N= 16. The target monitoring time per subject and group was five continuous impedance measurements; the mean monitoring time was 5.10 ± 0.49 (4.28 to 5.82) hours. There were no adverse events related to the test articles. The testing demonstrated gastric impedance measurements were performed safely and demonstrated XL measurement was an indirect and consistent marker of gastric mucosal perfusion in the subject animals, which shows significant and detectable changes before commonly used markers of global perfusion under hypovolemic shock conditions.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Mucosal Integrity Conductivity (MI) Test System (DEN180067), Nasogastric Feeding Tubes – ENFit Port – PVC (K213258)
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Entarik Feeding Tube (K230206)
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 876.1450 Esophageal tissue characterization system.
(a)
Identification. An esophageal tissue characterization system is a device intended for obtaining measurements of electrical properties within esophageal tissue.(b)
Classification. Class II (special controls). The special controls for this device are:(1) All patient contacting components of the device must be demonstrated to be biocompatible.
(2) Performance testing must demonstrate the device can accurately measure the designated electrical characteristics.
(3) Mechanical safety testing must demonstrate that the device will withstand forces encountered during use.
(4) Software verification, validation, and hazard analysis must be performed.
(5) Electromagnetic compatibility and electrical safety, mechanical safety, and thermal safety of the device must be performed.
(6) Performance data must validate the reprocessing instructions for any reusable components of the device.
(7) Labeling must include:
(i) Specific instructions regarding the proper placement and use of the device;
(ii) Instructions for reprocessing of any reusable components; and
(iii) An expiration date for single use components.
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.
September 6, 2024
Alandra Medical SAPI de CV % Randy Prebula Partner Hogan Lovells US LLP 555 Thirteenth Street, NW Washington, District of Columbia 20004
Re: K233974
Trade/Device Name: Mucosal Impedance Measurement System Regulation Number: 21 CFR 876.1450 Regulation Name: Esophageal Tissue Characterization System Regulatory Class: Class II Product Code: QIS, PIF Dated: August 6, 2024 Received: August 6, 2024
Dear Randy Prebula:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
1
(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Sivakami Venkatachalam -S
for Shanil P. Haugen, Ph.D. Assistant Director DHT3A: Division of Renal, Gastrointestinal, Obesity and Transplant Devices
2
OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: 07/31/2026 See PRA Statement below.
Submission Number (if known)
Device Name
Mucosal Impedance Measurement System
Indications for Use (Describe)
The Mucosal Impedance Measurement System is indicated for use by medical personnel trained in the usage of enteral feeding tubes for the treatment of adult patients requiring gastric decompression or enteral feeding for the delivery nutrition, fluids, and medications to the patient from an enteral feeding svringe or feedings set designed with ENFit connectors. The measurements of the Mucosal Impedance Measurement System are collected in patients indicated for enteral feeding. This product is single use for no longer than 24 hours.
The Mucosal Impedance Measurement System is equipped with sensors designed to collect and display real time and continuous gastric reactance "XL" measurements. The device is not for use as a sole diagnostic screening tool and is restricted to prescription use in a hospital environment.
Type of Use (Select one or both, as applicable)
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
510(k) SUMMARY
Alandra's Mucosal Impedance Measurement System
Submitter
Alandra Medical SAPI de CV Bosque de Alisos 17, Oficina 7 Bosques de las Lomas, Cuajimalpa de Morelos Mexico City, CDMX 05110 Mexico
Phone: 52 559950405
Contact Person: Montserrat Godinez Garcia
Date Prepared: August 6, 2024
Name of Device: Mucosal Impedance Measurement System
Classification Name: 876.1450 - Esophageal tissue characterization system
Regulatory Class: Class II
Product Code: QIS, PIF
Predicate Devices
Mucosal Integrity Conductivity (MI) Test System (DEN180067)
Nasogastric Feeding Tubes – ENFit Port – PVC (K213258)
Reference Devices
Entarik Feeding Tube (K230206)
Device Description
The Mucosal Impedance Measurement System senses passive electrical features of the gastric tissue that corelate to of epithelial integrity through a technique known as 'bioimpedance spectroscopy'. Bioimpedance spectroscopy measures the ability of tissue to conduct electricity (resistance) and the ability of tissue to store charged particles (reactance).
The Florence monitor model ISMO 1.0 is an electronic device that delivers electrical current to a small region of the gastric tissue through the Athena Catheter; the device measures the resultant voltage, and then calculates and displays impedance information in numeric and graphic representations. More specifically, to measure the bioimpedance of the gastric mucosa impedance, the device delivers electric current through the Athena Catheter. The resulting voltage developed between the two inner electrodes is sensed, filtered, amplified,
5
and then digitized by the electronic circuits of the monitor. Once the measured voltage from the gastric tissue has been digitized, a proprietary algorithm processes the information and calculates the impedance spectrum and the Central Reactance parameter (XL). The device displays the information as either a function of frequency or as a function of time.
Intended Use / Indications for Use
The Mucosal Impedance Measurement System is indicated for use by medical personnel trained in the usage of enteral feeding tubes for the treatment of adult patients requiring gastric decompression or enteral feeding for the delivery nutrition, fluids, and medications to the patient from an enteral feeding syringe or feedings set designed with ENFit connectors. The measurements of the Mucosal Impedance Measurement System are collected in patients indicated for enteral feeding. This product is single use for no longer than 24 hours.
The Mucosal Impedance Measurement System is equipped with sensors designed to collect and display real time and continuous gastric reactance "XL" measurements. The device is not for use as a sole diagnostic screening tool and is restricted to prescription use in a hospital environment.
The proposed indications differ from the predicate Mucosal Integrity Conductivity Test System (DEN180067) in that the predicate collects real time epithelial impedance measurements during endoscopy, whereas the Mucosal Impedance Measurement System collects impedance during nasogastric intubation. Additionally, the Mucosal Impedance Measurement System specifically outputs gastric reactance "XL" measurements. This difference does not alter the intended therapeutic use of the device as a tool for collecting impedance measurements in the upper gastric tract. When used as labeled, the impedance measurements for both the predicate and the Mucosal Impedance Measurement System are not for use as a sole diagnostic screening tool.
The enteral feeding part of the subject device's indications for use is similar to that for the Nasogastric Feeding Tubes predicate device (K213258). The inclusion of feeding tube functionality does not alter the safety profile of the risks for the proposed device remain as outlined in DEN180067 which are supported by the same mitiqation measures.
Furthermore, FDA has previously accepted the use of impedance sensors integrated into nasogastric tubes in the 510(k) cleared Entarik Feeding Tube (K230206). Although the indicated use of the impedance measurement in the Enatrik Feeding Tube is for confirming proper placement of the tube, the clearance demonstrates the suitability for evaluating the integration of impedance measurement technology into gastrointestinal tube and accessory devices.
Summary of Technological Characteristics
Impedance measurement of tissues in the upper gastric tract is the primary technological principle for both the subject and predicate Mucosal Integrity Conductivity (MI) Test System. Both the subject device and the predicate Nasogastric Feeding Tubes – ENFit Port – PVC (K213258) share the same technological principles to support enteral feeding and gastric
6
decompression. The proposed device functions by collecting and processing gastric impedance measurements using impedance measurement hardware integrated into the distal end of a gastric feeding tube. At a high level, the subject and predicate devices are based on the following same technological elements:
- Impedance collection hardware ●
- o Signal processing software
- Impedance based user output
- Consist of single use and reusable components ●
- Similar tube lengths and French sizes ●
- . Both tubes have markings and are radiopaque.
The following technological differences exist between the subject and predicate devices:
- Integration of impedance measurement hardware for the subject device into an . enteral feeding tube rather than endoscopic placement.
- The proposed device is only for use in adult patients in a hospital environment .
Performance Data - Summary of non-clinical bench studies
Non-clinical/bench studies conducted on the Mucosal Impedance Measurement System to demonstrate the safety and effectiveness of the device include Sterilization Validation, Packaging Validation, Shelf Life testing, Biocompatibility testing per ISO 10993-1, Software Verification and Validation, Electrical Safety and EMC testing, Performance testing for tensile properties, security of connectors, flow rate, and liquid leakage. The EnFit feeding connector of the Athena Catheter was tested per ISO 80369-3.
| Test | Methods |
|---|---|
| Flow rate | "Gravity Flow Rate Testing in Enteral Tubes" as described in |
| the "Catalog of Regulatory Science Tools to Help Assess New | |
| Medical Devices" | |
| Tensile strength | EN1615:2000 Enteral Feeding Catheters And Enteral Giving |
| Sets For Single Use And Their Connectors. Design And | |
| Testing (Section 4.1.1) | |
| EN1618:1997 Catheters other than intravascular catheters - | |
| Test methods for common properties (Annex B) | |
| Liquid leakage | EN1615:2000 Enteral Feeding Catheters And Enteral Giving |
| Sets For Single Use And Their Connectors. Design And | |
| Testing (Sections 4.1.3) | |
| EN1618:1997 Catheters other than intravascular catheters - | |
| Test methods for common properties (Annex C) | |
| Security of connectors | EN1615:2000 Enteral Feeding Catheters And Enteral Giving |
| Sets For Single Use And Their Connectors. Design And | |
| Testing (Sections 4.3.1) | |
| EN1618:1997 Catheters other than intravascular catheters - | |
| Test methods for common properties (Annex F) | |
| Flexibility | ASTM F3505-21 Standard Test Method for Stent and |
| Endovascular Prosthesis Kink Resistance | |
| EnFit connector | |
| (dimensional verification, | |
| rigidity, fluid leakage test, | |
| stress cracking, resistance | |
| to separation from axial | |
| load, resistance to | |
| separation from unscrewing, | |
| resistance to overriding, and | |
| disconnection by | |
| unscrewing) | ISO 80369-3:2016 Small-bore connectors for liquids and |
| gases in healthcare applications Part 3: Connectors for | |
| enteral applications | |
| Sterilization validation | ISO 11135:2014 Sterilization of health-care products |
| Ethylene oxide - Requirements for the development, | |
| validation and routine control of a sterilization process for | |
| medical devices | |
| Packaging validation | ISO 11607-1:2019 Packaging for terminally sterilized medical |
| devices - Part 1: Requirements for materials, sterile barrier | |
| systems and packaging systems | |
| Dimensional verification | Overall length, working length, catheter outer diameter, |
| catheter inner diameter, sensor dimensions, and spacing of | |
| the sensors | |
| Accuracy - thermal stability | Thermal stability of the sensors has been verified by |
| confirming that the measurements of the central reactance | |
| parameter (XL) remain consistent across a temperature range | |
| that covers the range 77-111°F (25-44°C). | |
| Stability of the sensors was confirmed in terms of the | |
| dispersion (standard deviation / interquartile range) of a | |
| statistically significative number of measurements across the | |
| temperature range. The PASS criterion was defined as | |
| confirming that at least 95% of all measurements are | |
| contained within a +/-1Ω tolerance. | |
| Accuracy - temporal stability | Temporal stability of the sensors was verified by confirming |
| that the measurements of the central reactance parameter | |
| (XL) remain consistent across 24 hours. | |
| Stability of the sensors was confirmed in terms of the | |
| dispersion (standard deviation / interquartile range) of a | |
| statistically significative number of measurements over the 24 | |
| period. The PASS criterion was defined as confirming that at least 95% of all measurements are contained within a +/-1Ω tolerance (which corresponds to the accuracy stated in the Instructions for Use). |
In all instances, the Mucosal Impedance Measurement System functioned as intended.
7
8
Biocompatibility
The Mucosal Impedance Measurement System is classified as mucosal membrane contacting for repeat, prolonged contact during clinical use(